IR@PKUHSC  > 北京大学第二临床医学院  > 血液科
学科主题临床医学
Haploidentical/Mismatched Hematopoietic Stem Cell Transplantation without In Vitro T Cell Depletion for T Cell Acute Lymphoblastic Leukemia
Wang, Yu; Liu, Dai-Hong; Xu, Lan-Ping; Liu, Kai-Yan; Chen, Huan; Chen, Yu-Hong; Han, Wei; Zhang, Xiao-hui; Huang, Xiao-Jun
关键词T cell acute lymphoblastic leukemia Hematopoietic stem cell transplantation Allogeneic HLA Haploidentical Mismatched
刊名BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
2012-05-01
DOI10.1016/j.bbmt.2011.08.024
18期:5页:716-721
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Hematology ; Immunology ; Transplantation
研究领域[WOS]Hematology ; Immunology ; Transplantation
关键词[WOS]DONOR LYMPHOCYTE INFUSION ; RELAPSE ; ADULTS ; TRIAL
英文摘要

The outcome of T cell acute lymphoblastic leukemia (T-ALL) is poorly understood. Allogeneic hematopoietic stem cell transplantation (HSCT) remains 1 of the best options to cure T-ALL. However, many patients cannot find an HLA-matched donor. Our institute established a new protocol for haplo-identical HSCT. Busulfan, cyclophosphamide, cytosine arabinoside, and methyl CCNU plus antithymocyte globulin was used for conditioning therapy. Seventy-two patients diagnosed with T-ALL underwent transplantation from haploidentical donor family members. The incidence rates of grades II to IV acute graft-versus-host disease (aGVHD) and of grades III and IV aGVHD were 49% +/- 12% and 19% 12%, respectively. The cumulative incidence rate for chronic GVHD (cGVHD) at 2 years after HSCT was 41% +/- 12%. After a median follow-up of 12 months, 15 patients had relapsed, 14 died from relapse, and 41 patients were still alive without disease recurrence. The probability of leukemia-free survival (LFS) was 44.2% +/- 7.4% at 3 years. Patients transplanted during their first complete remission (CRI) had a lower relapse rate (18.8% versus 37.5%, P = .049, with a relative risk [RR] = 0.247, P = .007), a lower nonrelapse mortality (NRM) rate (16.6% versus 50.0%, P = .046, with an RR = 0.279, P = .024), and better LFS (54.8% versus 12.5%, P = .001, with an RR = 0.315, P = .004) compared with patients transplanted beyond CRI. This study confirmed that haploidentical/mismatched HSCT could be an alternative treatment choice for T-ALL. Biol Blood Marrow Transplant 18: 716-721 (2012) (C) 2012 American Society for Blood and Marrow Transplantation

语种英语
WOS记录号WOS:000303558500009
项目编号30971292 ; 2008zx09312-026
资助机构National Natural Science Foundation of China ; National High-Tech R&amp ; D Program of China (863 Program) ; Ministry of Health of China ; National Scientific Major Program-major new drug formulation ; Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation
引用统计
被引频次:12[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/62430
专题北京大学第二临床医学院_血液科
医学人文研究院/公共教学部_哲学与社会科学系
作者单位Peking Univ, Peoples Hosp, Inst Hematol, Beijing 100044, Peoples R China
推荐引用方式
GB/T 7714
Wang, Yu,Liu, Dai-Hong,Xu, Lan-Ping,et al. Haploidentical/Mismatched Hematopoietic Stem Cell Transplantation without In Vitro T Cell Depletion for T Cell Acute Lymphoblastic Leukemia[J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION,2012,18(5):716-721.
APA Wang, Yu.,Liu, Dai-Hong.,Xu, Lan-Ping.,Liu, Kai-Yan.,Chen, Huan.,...&Huang, Xiao-Jun.(2012).Haploidentical/Mismatched Hematopoietic Stem Cell Transplantation without In Vitro T Cell Depletion for T Cell Acute Lymphoblastic Leukemia.BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION,18(5),716-721.
MLA Wang, Yu,et al."Haploidentical/Mismatched Hematopoietic Stem Cell Transplantation without In Vitro T Cell Depletion for T Cell Acute Lymphoblastic Leukemia".BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION 18.5(2012):716-721.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Wang, Yu]的文章
[Liu, Dai-Hong]的文章
[Xu, Lan-Ping]的文章
百度学术
百度学术中相似的文章
[Wang, Yu]的文章
[Liu, Dai-Hong]的文章
[Xu, Lan-Ping]的文章
必应学术
必应学术中相似的文章
[Wang, Yu]的文章
[Liu, Dai-Hong]的文章
[Xu, Lan-Ping]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。